Everybody’s Wearing a Glucose Patch in 2026—Here’s the Measurement Error That’s Making Healthy People Fear the Wrong Foods
OTC CGMs made glucose a consumer metric—but the line you’re watching is delayed, averaged, and easy to moralize. The biggest “spikes” are where interpretation is least reliable.
By TheMurrow Editorial
March 7, 2026
Key Points
- 1Track the mechanism: wellness CGMs read interstitial fluid, not real-time blood glucose—so post-meal “spikes” can be delayed and misread.
- 2Question precision: MARD is an average, and accuracy shifts during rapid changes and low ranges—tiny peak differences often aren’t meaningful.
- 3Use context over blame: sleep, stress, and movement can reshape curves; single-meal verdicts can drive anxiety and needless restriction.
A small white patch on an upper arm used to signal something private: diabetes management, insulin dosing, a life organized around numbers. In 2026, the same patch shows up at dinner parties and on morning runs—worn by people who don’t have diabetes and aren’t trying to treat a disease. They’re trying to “understand their body.” Or, more often, to control it.
The cultural shift didn’t happen because millions suddenly became medically at risk. It happened because the monitors became easy to buy, easy to wear, and easy to misread. When a chart turns lunch into a moral referendum—green for virtue, red for failure—humans predictably start editing their lives around it.
There’s a reason glucose patches are everywhere, and it’s not just good engineering. It’s distribution, regulation, and a powerful modern fantasy: that a single stream of data can tell you which foods deserve your trust.
“A glucose trace feels like truth because it’s continuous. But continuity is not the same thing as certainty.”
— — TheMurrow Editorial
This is the part most “glucose hacking” content skips: these devices are measuring something real, but not always what wearers think they’re measuring—and the moments people fixate on (spikes, dips, dramatic after-meal arcs) are exactly where interpretation gets tricky.
The OTC inflection point: how glucose monitoring left the clinic
The wellness CGM boom has a clear hinge year: 2024. That’s when the U.S. regulatory and retail story changed in a way social media could finally exploit.
On March 5, 2024, the FDA cleared Stelo by Dexcom as the first over-the-counter glucose biosensor—no prescription required, a milestone Dexcom announced publicly in its investor news release. A device category associated with chronic disease management suddenly became a consumer product.
Three months later, on June 10, 2024, Abbott announced FDA clearance for two OTC continuous glucose monitoring systems, positioned for people not using insulin and framed around broader, non-dosing use cases. Then on September 5, 2024, Abbott said Lingo would be available OTC in the U.S., explicitly pitched for “overall health and wellness,” not insulin dosing—reported widely, including by CNBC.
The distribution story came next. In October 2025, Axios reported that Walmart would carry Abbott’s Lingo in thousands of U.S. stores. That detail matters more than it sounds. When a device moves from niche online channels into big-box retail, it stops being a hobbyist’s tool and becomes an impulse buy.
On March 5, 2024, the FDA cleared Stelo by Dexcom as the first over-the-counter glucose biosensor—no prescription required, a milestone Dexcom announced publicly in its investor news release. A device category associated with chronic disease management suddenly became a consumer product.
Three months later, on June 10, 2024, Abbott announced FDA clearance for two OTC continuous glucose monitoring systems, positioned for people not using insulin and framed around broader, non-dosing use cases. Then on September 5, 2024, Abbott said Lingo would be available OTC in the U.S., explicitly pitched for “overall health and wellness,” not insulin dosing—reported widely, including by CNBC.
The distribution story came next. In October 2025, Axios reported that Walmart would carry Abbott’s Lingo in thousands of U.S. stores. That detail matters more than it sounds. When a device moves from niche online channels into big-box retail, it stops being a hobbyist’s tool and becomes an impulse buy.
2024
The hinge year when FDA OTC clearances turned CGMs from clinic tools into consumer products.
March 5, 2024
FDA cleared Stelo by Dexcom as the first OTC glucose biosensor—no prescription required.
October 2025
Axios reported Walmart would carry Abbott’s Lingo in thousands of U.S. stores—mainstream retail scale, not niche adoption.
Who’s wearing them now—and why
In the business press, the rise of non-diabetic CGM use has been tracked as a social-media-driven trend: people ranking foods, “avoiding spikes,” and treating a glucose curve like a personality test. The Forbes narrative around “glucose hacking” reflects a key cultural claim: that any spike is bad. That claim is not established by the research cited here, but it is influential—and it shapes how consumers interpret their data.
The question for readers isn’t whether CGMs “work.” The question is whether wellness users are using the right tool for the right job, and whether the job they’ve assigned it—minute-by-minute moral judgment—is even coherent.
The question for readers isn’t whether CGMs “work.” The question is whether wellness users are using the right tool for the right job, and whether the job they’ve assigned it—minute-by-minute moral judgment—is even coherent.
“The monitors didn’t just get better. They got easier to buy—and easier to obsess over.”
— — TheMurrow Editorial
What a CGM actually measures (and what it doesn’t)
A continuous glucose monitor feels like a direct window into “blood sugar.” Most people assume the line on the app is a near-instant reading of blood glucose. That isn’t what these sensors measure.
CGMs generally measure glucose in interstitial fluid (ISF)—the fluid between cells—rather than directly in capillary blood. The distinction is not academic. It matters most when glucose is changing quickly: after meals, during exercise, under stress, or when sleep is disrupted.
A commonly described phenomenon in educational and clinical sources is physiologic lag between blood and ISF glucose. Even with a “perfect” sensor, ISF values reflect blood glucose with a delay often described as roughly 5–15 minutes, and sometimes longer during rapid shifts such as exercise. One review accessible via PubMed Central discusses this lag and the underlying dynamics.
CGMs generally measure glucose in interstitial fluid (ISF)—the fluid between cells—rather than directly in capillary blood. The distinction is not academic. It matters most when glucose is changing quickly: after meals, during exercise, under stress, or when sleep is disrupted.
A commonly described phenomenon in educational and clinical sources is physiologic lag between blood and ISF glucose. Even with a “perfect” sensor, ISF values reflect blood glucose with a delay often described as roughly 5–15 minutes, and sometimes longer during rapid shifts such as exercise. One review accessible via PubMed Central discusses this lag and the underlying dynamics.
5–15 minutes
Commonly described physiologic lag between blood glucose changes and interstitial-fluid (ISF) readings—often most noticeable after meals or during exercise.
The problem with “post-meal spike” culture
The moments that feel most instructive to wellness users—“Look what that rice did to me!”—are often the moments when lag matters most. When glucose rises quickly after eating, the sensor’s estimate may trail what a fingerstick would show at the same instant. When glucose falls quickly, the same lag can make a drop look delayed or oddly shaped.
None of this means CGMs are “wrong.” It means they are measuring a different compartment of your physiology, with timing dynamics that are easy to forget when a graph updates every few minutes.
Practical implication: when someone compares two lunches and declares one “safe” because the CGM line rose less, they may be comparing not only different foods, but different timing—sleep, stress, walk after lunch, hydration, and sensor lag all bundled into one tidy story.
None of this means CGMs are “wrong.” It means they are measuring a different compartment of your physiology, with timing dynamics that are easy to forget when a graph updates every few minutes.
Practical implication: when someone compares two lunches and declares one “safe” because the CGM line rose less, they may be comparing not only different foods, but different timing—sleep, stress, walk after lunch, hydration, and sensor lag all bundled into one tidy story.
“Your CGM isn’t a courtroom verdict on lunch. It’s a sensor reading interstitial fluid with a time delay.”
— — TheMurrow Editorial
Accuracy headlines and the trap of the average
Manufacturers and reviewers often summarize CGM accuracy with a single number: MARD, or Mean Absolute Relative Difference. Lower is better. It’s the metric most likely to be quoted in marketing materials and tech coverage, and it’s useful as far as it goes.
A key limitation is embedded in the name: MARD is an average. Averages can conceal the exact situations where wellness users become most reactive:
- performance differences during rapid glucose changes
- weaker accuracy in low glucose ranges
- sensor artifacts that produce transient “events” that aren’t physiologic
Abbott’s professional materials for FreeStyle Libre 3 cite an overall MARD around 7.8%. Dexcom communications have cited figures around ~8% for G7 variants, noting that exact specifications can depend on model, region, and wear conditions (the labeling is where the final numbers live).
Here’s where the consumer misunderstanding blooms. A “7–8% MARD” does not mean your sensor can cleanly adjudicate tiny differences in post-lunch peaks.
A key limitation is embedded in the name: MARD is an average. Averages can conceal the exact situations where wellness users become most reactive:
- performance differences during rapid glucose changes
- weaker accuracy in low glucose ranges
- sensor artifacts that produce transient “events” that aren’t physiologic
Abbott’s professional materials for FreeStyle Libre 3 cite an overall MARD around 7.8%. Dexcom communications have cited figures around ~8% for G7 variants, noting that exact specifications can depend on model, region, and wear conditions (the labeling is where the final numbers live).
Here’s where the consumer misunderstanding blooms. A “7–8% MARD” does not mean your sensor can cleanly adjudicate tiny differences in post-lunch peaks.
7.8%
Abbott professional materials cite an overall MARD around 7.8% for FreeStyle Libre 3—a useful average that can hide variability.
~8%
Dexcom communications cite figures around ~8% for G7 variants, with final specs depending on labeling, model, and conditions.
A concrete way to think about it
Suppose a wellness user sees a peak of 142 mg/dL after one meal and 128 mg/dL after another and concludes the first meal is “bad.” With an average relative difference on the order of ~8%, plus physiologic lag and normal biological variability, that level of precision may be illusory—especially during fast changes, where comparisons to blood glucose are least straightforward.
A 2024 systematic review (PubMed Central) summarizes the broader scientific view: CGM accuracy is often “adequate” in many ranges, but accuracy metrics can vary materially by setting, and very poor MARD values have been reported at very low glucose thresholds in some studies. For wellness users chasing fine-grained food rankings, that nuance matters.
The sophisticated takeaway isn’t “ignore the device.” It’s “stop pretending the app offers lab-grade certainty about every bite.”
A 2024 systematic review (PubMed Central) summarizes the broader scientific view: CGM accuracy is often “adequate” in many ranges, but accuracy metrics can vary materially by setting, and very poor MARD values have been reported at very low glucose thresholds in some studies. For wellness users chasing fine-grained food rankings, that nuance matters.
The sophisticated takeaway isn’t “ignore the device.” It’s “stop pretending the app offers lab-grade certainty about every bite.”
Key Insight
A “good” MARD headline doesn’t grant meal-by-meal precision—especially during rapid post-meal changes where ISF lag and variability are highest.
The measurement glitches that can send you after the wrong foods
People tend to interpret CGM data as a clean story: you eat, glucose rises, you learn. Real-world sensors tell messier stories, and wellness users often respond by punishing the wrong variable.
Even without adding new claims beyond the research here, the structural issue is clear: wellness users often turn CGM readings into food-ranking systems. That magnifies the impact of small errors, lag, and variability. A minor artifact becomes a sweeping dietary rule.
Even without adding new claims beyond the research here, the structural issue is clear: wellness users often turn CGM readings into food-ranking systems. That magnifies the impact of small errors, lag, and variability. A minor artifact becomes a sweeping dietary rule.
Why the “most dramatic” moments are the least stable
Physiologic lag (often ~5–15 minutes) becomes most visible during sharp rises and falls. Those sharp moments are also the ones most likely to provoke behavioral overcorrection: skipping fruit, demonizing rice, cutting carbs more aggressively than intended, or using a single “bad graph” to justify restrictive eating.
Meanwhile, the same meal eaten under different circumstances can produce different traces:
- A walk after eating can blunt and reshape the curve.
- Sleep quality can alter glucose dynamics the next day.
- Stress can shift glucose patterns independent of food.
None of those points require exotic mechanisms; they are ordinary human variability. Yet the device’s clean line encourages a clean explanation. Humans prefer a villain, and the easiest villain is whatever you just ate.
Meanwhile, the same meal eaten under different circumstances can produce different traces:
- A walk after eating can blunt and reshape the curve.
- Sleep quality can alter glucose dynamics the next day.
- Stress can shift glucose patterns independent of food.
None of those points require exotic mechanisms; they are ordinary human variability. Yet the device’s clean line encourages a clean explanation. Humans prefer a villain, and the easiest villain is whatever you just ate.
A real-world case: the salad that “spiked”
A common scenario among wellness users goes like this: someone eats a “healthy” meal—say a salad with chicken—then sees a noticeable rise on the CGM and panics. They conclude the dressing is toxic, the carrots are “too sugary,” or they can’t “handle” tomatoes.
What’s missing is context: timing, lag, and the reality that glucose changes are not controlled experiments. If the person checked the CGM during a rapid upswing, the ISF reading may be catching up. If they were stressed, sleep-deprived, or had exercised earlier, the curve might not mean what they think it means.
The lesson isn’t that CGMs are useless. It’s that single-meal, single-day interpretation is a poor basis for dietary law.
What’s missing is context: timing, lag, and the reality that glucose changes are not controlled experiments. If the person checked the CGM during a rapid upswing, the ISF reading may be catching up. If they were stressed, sleep-deprived, or had exercised earlier, the curve might not mean what they think it means.
The lesson isn’t that CGMs are useless. It’s that single-meal, single-day interpretation is a poor basis for dietary law.
Why “any spike is bad” became persuasive—and what it costs
The cultural messaging around wellness CGMs often reduces metabolism to a single imperative: avoid spikes. It’s a compelling simplification because it feels actionable. You can swap foods and watch the line respond. You can buy certainty.
Business coverage of the trend has described exactly that: social-media-driven adoption paired with a fear-based interpretation of normal physiology—where any rise is treated as damage. That framing sells subscriptions and affiliate links because it encourages constant vigilance.
Business coverage of the trend has described exactly that: social-media-driven adoption paired with a fear-based interpretation of normal physiology—where any rise is treated as damage. That framing sells subscriptions and affiliate links because it encourages constant vigilance.
The psychological loop: numbers, anxiety, restriction
For some users, CGMs become less about insight and more about surveillance. The pattern can look like:
- Wear sensor
- See a peak
- Assign blame to a food
- Restrict the food
- Feel temporary control
- Repeat
If the underlying premise is flawed—if normal glucose variability is being misread as pathology—then the loop produces anxiety and unnecessary restriction. Even for disciplined readers, the data can pull attention away from the basics of health: dietary quality, regular movement, sleep, stress management.
A more adult relationship with the data recognizes tradeoffs. Sometimes a meal produces a higher curve because it contained more carbohydrate. That fact alone doesn’t settle whether it was a good meal in the larger context of nutrition, satiety, training, and lifestyle.
- Wear sensor
- See a peak
- Assign blame to a food
- Restrict the food
- Feel temporary control
- Repeat
If the underlying premise is flawed—if normal glucose variability is being misread as pathology—then the loop produces anxiety and unnecessary restriction. Even for disciplined readers, the data can pull attention away from the basics of health: dietary quality, regular movement, sleep, stress management.
A more adult relationship with the data recognizes tradeoffs. Sometimes a meal produces a higher curve because it contained more carbohydrate. That fact alone doesn’t settle whether it was a good meal in the larger context of nutrition, satiety, training, and lifestyle.
“When a graph becomes a morality play, the body always loses.”
— — TheMurrow Editorial
Using a CGM like an instrument, not an oracle
Wellness CGMs can be used intelligently—especially when users treat them as instruments with known limitations rather than omniscient truth machines.
Start with the basic technical humility implied by the research: CGMs measure ISF glucose; they lag behind blood glucose during rapid changes; accuracy is summarized with averages like MARD that hide variability; and performance can differ by conditions and ranges.
Start with the basic technical humility implied by the research: CGMs measure ISF glucose; they lag behind blood glucose during rapid changes; accuracy is summarized with averages like MARD that hide variability; and performance can differ by conditions and ranges.
Practical rules for sane interpretation
If you’re wearing an OTC CGM for wellness, a few guardrails can prevent the most common mistakes:
- Look for patterns, not verdicts. One day’s trace is not a study.
- Respect timing. During rapid changes (post-meal, exercise), remember the ~5–15 minute physiologic lag commonly described in clinical education sources.
- Avoid micro-ranking foods by tiny differences. A MARD headline around 7–8% should warn you off declaring meaningful victory because one peak was 10–15 points lower.
- Use context notes. Sleep, stress, exercise, and meal composition matter; write them down before you blame a single ingredient.
- Treat extreme lows cautiously. The 2024 systematic review notes that very low glucose ranges can show much poorer performance in some studies. Don’t self-diagnose a dangerous low based on a single reading without appropriate confirmation and guidance.
- Look for patterns, not verdicts. One day’s trace is not a study.
- Respect timing. During rapid changes (post-meal, exercise), remember the ~5–15 minute physiologic lag commonly described in clinical education sources.
- Avoid micro-ranking foods by tiny differences. A MARD headline around 7–8% should warn you off declaring meaningful victory because one peak was 10–15 points lower.
- Use context notes. Sleep, stress, exercise, and meal composition matter; write them down before you blame a single ingredient.
- Treat extreme lows cautiously. The 2024 systematic review notes that very low glucose ranges can show much poorer performance in some studies. Don’t self-diagnose a dangerous low based on a single reading without appropriate confirmation and guidance.
Sane CGM Guardrails (Wellness Use)
- ✓Look for patterns, not verdicts.
- ✓Respect timing and the ~5–15 minute ISF lag.
- ✓Avoid micro-ranking foods by tiny peak differences.
- ✓Write context notes: sleep, stress, exercise, and meal composition.
- ✓Treat extreme lows cautiously; confirm and seek medical guidance when needed.
A more useful “case study”: the walk-after-dinner experiment
If you want an experiment that respects what CGMs can do well, try this: keep dinner roughly consistent for a week and change only one variable—take a 10–20 minute walk after eating on some nights, sit on others, and compare the general shape over multiple days.
That approach reduces the temptation to villainize a single food and instead uses the device to observe a behavioral lever. It also aligns with the reality that CGMs are better at revealing trends over time than adjudicating the moral status of blueberries.
That approach reduces the temptation to villainize a single food and instead uses the device to observe a behavioral lever. It also aligns with the reality that CGMs are better at revealing trends over time than adjudicating the moral status of blueberries.
A Better CGM Experiment Than Food-Ranking
- 1.Keep dinner roughly consistent for a week.
- 2.On some nights, take a 10–20 minute walk after eating; on others, don’t.
- 3.Compare the overall curve shape across multiple days, not one-night “wins.”
The industry’s role: responsible access versus responsible interpretation
The companies moving into OTC wellness markets have generally been careful in how they position products: Abbott framed Lingo around “overall health and wellness,” explicitly not insulin dosing. That matters. It reflects an understanding that the device is entering a new user population with different risks—not of hypoglycemia from insulin, but of misunderstanding and overcorrection.
The retail expansion—especially Walmart carrying Lingo in thousands of stores, per Axios—raises a tougher question: what does consumer education look like when a medical-adjacent sensor sits near the pharmacy aisle like a fitness tracker?
The retail expansion—especially Walmart carrying Lingo in thousands of stores, per Axios—raises a tougher question: what does consumer education look like when a medical-adjacent sensor sits near the pharmacy aisle like a fitness tracker?
Two legitimate perspectives can both be true
A fair editorial view has to hold two ideas at once:
1. More access can be good. OTC availability lowers friction for people with prediabetes risk concerns, family history, or those seeking better lifestyle awareness.
2. More access can also amplify misinterpretation. When the prevailing online narrative says “any spike is bad,” easier access can scale anxiety, orthorexia-adjacent behaviors, and confused nutrition logic.
The most responsible path is not gatekeeping by default. It’s building better norms: clear explanations of ISF versus blood glucose, candid discussions of lag, and a public understanding that “accuracy” is a distribution, not a single flattering number.
1. More access can be good. OTC availability lowers friction for people with prediabetes risk concerns, family history, or those seeking better lifestyle awareness.
2. More access can also amplify misinterpretation. When the prevailing online narrative says “any spike is bad,” easier access can scale anxiety, orthorexia-adjacent behaviors, and confused nutrition logic.
The most responsible path is not gatekeeping by default. It’s building better norms: clear explanations of ISF versus blood glucose, candid discussions of lag, and a public understanding that “accuracy” is a distribution, not a single flattering number.
Editor’s Note
The central risk for many wellness users isn’t insulin-related hypoglycemia—it’s misinterpretation: lag, averages, and artifacts turning normal variability into fear-driven restriction.
Conclusion: the patch is real; the story you tell from it is optional
OTC CGMs became a consumer phenomenon because of identifiable, recent shifts: FDA clearances in 2024 (Dexcom’s Stelo and Abbott’s OTC systems, including Lingo) and retail distribution that made sensors mainstream by 2025. The technology is impressive. The cultural interpretation is where things get shaky.
A CGM can help you notice patterns. It can also coax you into a false precision—treating a delayed, averaged, context-dependent signal as an immediate verdict on virtue. The same graph that nudges one person toward healthier routines can push another toward needless restriction.
The question isn’t whether you should wear the patch. The question is whether you’re willing to read it like an adult: with curiosity, context, and a respectful suspicion of simple stories.
A CGM can help you notice patterns. It can also coax you into a false precision—treating a delayed, averaged, context-dependent signal as an immediate verdict on virtue. The same graph that nudges one person toward healthier routines can push another toward needless restriction.
The question isn’t whether you should wear the patch. The question is whether you’re willing to read it like an adult: with curiosity, context, and a respectful suspicion of simple stories.
T
About the Author
TheMurrow Editorial is a writer for TheMurrow covering health & wellness.
Frequently Asked Questions
Are OTC CGMs FDA-cleared for people without diabetes?
Yes—several major milestones happened in 2024. Dexcom’s Stelo was cleared by the FDA on March 5, 2024 as the first over-the-counter glucose biosensor. Abbott announced FDA clearance for two OTC CGMs on June 10, 2024, and said Lingo would be available OTC in the U.S. on September 5, 2024, framed around wellness rather than insulin dosing.
Does a CGM measure blood glucose?
Not directly. CGMs generally measure glucose in interstitial fluid (ISF) rather than capillary blood. The two are related, but they aren’t identical—especially when glucose is changing quickly. That distinction explains why a CGM trace can look “late” compared with a fingerstick or why post-meal curves can be easy to overinterpret.
Why does my CGM “lag” after meals or exercise?
Physiologic lag is a known feature of ISF-based measurement. Educational and clinical sources commonly describe a lag of roughly 5–15 minutes, depending on how fast glucose is changing, and it can be longer during rapid shifts such as exercise. That lag can make the most dramatic parts of your graph the least comparable to real-time blood glucose.
What does MARD actually tell me about accuracy?
MARD (Mean Absolute Relative Difference) is an average error metric: lower numbers generally indicate better accuracy across a dataset. Abbott materials for Libre 3 cite an overall MARD around 7.8%, and Dexcom communications have cited figures around ~8% for G7 variants (specs vary by model/labeling). The key point: an average can hide worse performance in certain ranges or conditions.
Can I use a CGM to rank foods by “good” and “bad”?
You can compare patterns, but fine-grained ranking is risky. The combination of ISF lag, day-to-day biological variability, and the fact that accuracy metrics like MARD are averages means small differences—especially during fast post-meal changes—may not be meaningful. A better use is watching multi-day trends and testing one variable at a time (meal timing, walking after dinner, sleep).
What’s the most responsible way to use a wellness CGM?
Use it to learn patterns, not to prosecute single meals. Track context (sleep, stress, exercise), avoid overreacting to small peak differences, and remember that the device measures ISF with time lag. If you see readings that worry you—especially low values—avoid self-diagnosis based solely on the sensor and seek appropriate medical guidance and confirmation.
